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permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.SUMMARYJoint injury and osteoarthritis affect millions of people worldwide, but attempts to generate articular cartilage using adult stem/progen-
itor cells have been unsuccessful.We hypothesized that recapitulation of the humandevelopmental chondrogenic programusing plurip-
otent stem cells (PSCs) may represent a superior approach for cartilage restoration. Using laser-capture microdissection followed by
microarray analysis, we first defined a surface phenotype (CD166low/negCD146low/negCD73+CD44lowBMPR1B+) distinguishing the earliest
cartilage committed cells (prechondrocytes) at 5–6 weeks of development. Functional studies confirmed these cells are chondrocyte pro-
genitors. From 12 weeks, only the superficial layers of articular cartilage were enriched in cells with this progenitor phenotype. Isolation
of cells with a similar immunophenotype from differentiating human PSCs revealed a population of CD166low/negBMPR1B+ putative
cartilage-committed progenitors. Taken as a whole, these data define a developmental approach for the generation of highly purified
functional human chondrocytes from PSCs that could enable substantial progress in cartilage tissue engineering.INTRODUCTION
Articular cartilage is a highly specialized tissue formed from
chondrocytes that protects the bones of diarthrodial joints
from forces associated with load bearing and impact and
allows nearly frictionless motion between the articular sur-
faces (Buckwalter and Mankin, 1998). Cartilage injury and
lack of cartilage regeneration often lead to osteoarthritis
involving degradation of joints, including articular carti-
lage and subchondral bone. Osteoarthritis currently affects
more than 20 million people in the United States alone,
making joint-surface restoration a major priority in mod-
ern medicine (Andersson et al., 2011).
Articular chondrocytes are formed during the process of
endochondral ossification and joint formation during early
embryogenesis (DeLise et al., 2000; Goldring et al., 2006).
Different cartilage cell subsets formed during the process
of endochondral ossification have been primarily defined
based on theirmorphological appearance. First, themesen-
chymal cells of the lateral plate mesoderm condense toStem Cell Rform compact nodules and then differentiate into rapidly
dividing prechondrocytes, or transient progenitors, repre-
senting the transition of mesenchymal ancestors into
chondrocytes (Hall and Miyake, 1995; Woods et al.,
2007). Differentiating chondrocytes generated from pre-
chondrocytes continue to divide but also secrete carti-
lage-specific matrix to form the cartilage template of the
bone. There are twomajor types of chondrocytes generated
at this stage: (1) periarticular chondrocytes located in the
presumptive joint regions (also known as the interzone)
that later will form phenotypically stable or ‘‘permanent’’
articular cartilage (Koyama et al., 2008) and (2) growth
plate chondrocytes undergoing proliferation required
for bone growth that will eventually express collagen X
(COL10A1), undergo hypertrophic transformation, and
be replaced by bone (Provot and Schipani, 2005). One
defining feature of developing articular chondrocytes
is their progression through an intermediate expressing
growth differentiation factor 5 (GDF5), a ligand for
bone morphogenetic protein receptor 1 beta (BMPR1B),eports j Vol. 1 j 575–589 j December 17, 2013 j ª2013 The Authors 575
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Chondrogenic Differentiation of Human PSCsignaling through which is required for cartilage develop-
ment (Baur et al., 2000; Koyama et al., 2008).
Different cell types have been studied with respect to
their ability to generate articular cartilage. However, none
of the current cell-based repair strategies, including in-vi-
tro-expanded articular chondrocytes or mesenchymal
stem cells (MSCs) from adult bone marrow (BM), adipose
tissue, synovium, or amniotic fluid, have generated long-
lasting hyaline articular cartilage tissue (Gelse et al., 2008;
van Osch et al., 2009). It is not completely clear why adult
MSCs from all tested sources fail to generate hyaline artic-
ular cartilage. Potentially, the developmental origins of
adult MSCs and articular chondrocytes are different. Bona
fide cartilage progenitors are likely to be present only early
in development. Recapitulation of the human develop-
mental chondrogenic program and generation of chondro-
cytes from pluripotent stem cells (PSCs) may represent a
superior approach for cartilage restoration. Human PSCs
have been successfully used by several groups, including
ours, to generate cartilage-like tissue (Evseenko et al.,
2010; Nakayama et al., 2003; Oldershaw et al., 2010; Toh
et al., 2009; Yamashita et al., 2010; Umeda et al., 2012).
Some of these published reports involved undifferentiated
PSCs as a starting population to make cartilage-like tissue
(Oldershaw et al., 2010), while others utilized PSC-derived
MSCs as a source for chondrocytes (Nakayama et al., 2003;
Umeda et al., 2012). Differentiation of PSCs rarely yields a
single cell type, even under optimized conditions, necessi-
tating purification of the cell of interest from other deriva-
tives. None of the previously published studies have
reported the generation of a highly purified population of
PSC-derived chondrocytes, but rather demonstrated the
generation of undefined and unsorted cells with unknown
ontogeny capable of depositing chondrogenic matrix mol-
ecules. As a result, immunophenotypes and functional
characteristics of the earliest cartilage cells derived during
differentiation of PSCs are currently not known. To a large
extent, this knowledge is missing due to the complete lack
of the developmental studies dissecting the earliest stages
of human chondrogenesis.
Here, we define the developmental progression through
which primordial mesenchymal cells commit to the chon-
drocyte lineage in vivo. The application of laser-capture
microdissection (LCM) and gene expression profiling to
human limbs from 5 to 6 weeks of development allowed
us to determine candidate cell surface markers and
signaling pathways that distinguish the earliest primitive
chondrogenic progenitors (prechondrocytes) from other
cell types present in the same tissue. Moreover, this pheno-
type also delineated a subset of cells present in the periar-
ticular region in fetal and adult joints, which evidenced
localization and gene expression characteristic of resting
(immature) chondrocytes; these data suggest that BMPR1B576 Stem Cell Reports j Vol. 1 j 575–589 j December 17, 2013 j ª2013 Thedistinguishes immature from more differentiated and hy-
pertrophic chondrocytes at fetal and adult stages of human
development. Finally, application of this developmentally
defined paradigm enabled the directed differentiation of
PSCs into immature chondrocytes capable of integrating
into fetal joints in vitro and producing matrix. Taken as a
whole, these data define a developmental approach for
the generation of highly purified functional human chon-
drocytes from PSCs that could enable substantial progress
in cartilage tissue engineering.RESULTS
Identification of Molecular Markers Distinguishing
Prechondrocytes and Other Cell Lineages in
Developing Limbs
Chondrogenic development in the proximal regions of
the limbs occurs earlier than the distal ones and at
5-6 weeks of human embryogenesis, after the anatomically
defined cartilaginous anlagen of long bones such as the
humerus has already formed, groups of undifferentiated
prechondrocytes remain in distinct sites of the limbs (Fig-
ure 1A). Cartilage-committed mesenchymal cells (pre-
chondrocytes) could be identified as nodules with a
morphologically ‘‘dense’’ appearance in chondrogenic
condensations at weeks 5–6 and minimally stained with
cresyl violet, suggesting that they produced little cartilagi-
nous matrix (Figure 1B). Prechondrocytes from 5- to
6-week-old human limbs were isolated using LCM (Fig-
ure 1B; N = 6) and subjected to genome-wide expression
analysis. To nominate candidate genes that distinguish
prechondrocytes from other cell types in the limb at this
embryonic stage, RNA was isolated from the same speci-
mens following LCM of prechondrocytes and used for
microarray analysis.
Ingenuity Pathway Analysis (IPA) revealed 585 genes
significantly differentially expressed in prechondrocytes
versus total limb cells, which at this stage includes
myoblasts, blood, endothelial cells, keratinocytes, mature
chondrocytes, nerves, dermal fibroblasts, and other cell
types (Figure 1C; Table 1). Many of the genes enriched in
human prechondrocytes (Table 1A; Table S1 available on-
line) were previously found at the initial stages of chondro-
genesis in the chick ormouse embryo, indicating the purity
of LCM-isolated prechondrocytes. These genes included
SOX5, SOX6, SOX9, NKX 3-2, FOXP4, GDF5, PCDH8 and
PCDH10, BMPR1B, and PTCH1 (Table 1; Cameron et al.,
2009; DeLise et al., 2000; Goldring et al., 2006). In agree-
ment with these data, principal component analysis car-
ried out on total expression data (Figure 1D) demonstrated
that all six replicates of prechondrocyte data clustered
together and distinctly from total limb cells.Authors
Figure 1. Prechondrocytes Represent a Transcriptionally
Distinct Population in Developing Limbs
(A) Schematic representation of chondrocyte commitment and
maturation in the early human limb. Light blue spheres represent
condensing cartilage-committed mesenchymal cells.
(B) Representative image of chondrogenic regions before and after
laser-capture dissection. Sections were prestained with cresyl
violet. Scale bar, 100 mm.
(C) Unsupervised gene cluster analysis of significantly differentially
expressed genes in laser-capture microdissected prechondrocytes
(PC) from 5- to 6-week specimens versus total limb cells (TLC) from
the same specimen.
(D) Principal component analysis demonstrated the reproducibility
of data between biological replicates.
See also Table S1.
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we performed immunohistochemistry (IHC) to localize
commonly usedmesenchymal markers and the cell surface
markers identified in the microarray study. Expression of
these candidates was evaluated on both prechondrocytes
(Figures 2A and 2B) present in the less differentiatedStem Cell Rperipheral regions of condensations and themore differen-
tiated chondrocytes present in both the central zones at 6–
7 weeks of development (Figure 2B) as well as long bones in
the proximal regions (Figures 2A and 2C). All analyzed
markers could be divided into three groups based on the
pattern of antigen expression on prechondrocytes and
more mature, matrix-producing chondrocytes. In the first
group of tested antigens, low expression levels were found
in prechondrocytes (undergoing de novo chondrogenic
commitment) located in the periphery of forming conden-
sation and high expression detected in more mature chon-
drocytes located in the central part of the anlagen. This
pattern was detected for CD44 (Figure 2B) and also for
several other molecules including Syndecan 4 (SDC4),
FGFR2, and PTCH1 (Figure S1). The level of CD44 expres-
sion was most different between prechondrocytes and
more mature chondrocytes. The second group of antigens
showed declining expression levels from condensed pre-
chondrocytes to differentiated chondrocytes. This pattern
was detected for CD146 and CD166 (Figure 2B), as well as
CD56/neural cell adhesion molecule 1 (NCAM1) and pro-
tocadherins (PCDH) 8 and 10 (Figure S1). The third group
of antigens showed no difference in expression between
prechondrocytes and mature chondrocytes, including
CD73, BMPR1B (expressed in both cell types at this early
stage of development; Figures 2B and 2C), and CD34 (ex-
pressed at low or undetectable levels in both cell types; Fig-
ure S1). CD166 was clearly expressed in the primitive
mesenchymal cells surrounding chondrogenic condensa-
tions and was significantly downregulated on prechondro-
cytes and absent onmature chondrocytes. As expected, the
vast majority of prechondrocytes were dividing as detected
by Ki67 staining (Figures 2A and 2B). These data confirmed
the gene expression data and indicated that separation of
prechondrocytes from total limb cells, including more
differentiated mature chondrocytes, may be possible with
surface markers.
Defining Molecular Landmarks of Prechondrocyte
Differentiation and Maturation
We next wanted to identify surface markers that would
demarcate definitive resting (immature) periarticular chon-
drocytes from hypertrophic chondrocytes during their
maturation from prechondrocytes. To define molecular
markers during the process of prechondrocyte maturation,
resting periarticular chondrocytes were dissected from
femoral bone epiphysis of 17-week specimens (Figure 3A)
and compared with prechondrocytes dissected with LCM
from 5- to 6-week-old specimens. We use the term ‘‘resting
periarticular chondrocytes’’ for dissected cells (200 mm
layer) to emphasize that dissected cells were clearly sepa-
rated from more mature proliferating and hypertrophic
chondrocytes in the forming growth plate. Our studieseports j Vol. 1 j 575–589 j December 17, 2013 j ª2013 The Authors 577
Table 1. Transcriptional Signatures of Cartilage Cells at Different Stages of Human Development
Prechondrocytes versus Total Limb
Cells at 5–6 Weeks
Embryonic Prechondrocytes at 5–6 Weeks versus Immature Resting Fetal Chondrocytes
at 17 Weeks
Gene
Symbol p Value
Fold
Change Gene Symbol p Value
Fold
change Gene Symbol p Value
Fold
Change
Receptors and Adhesion Molecules Receptors and Adhesion Molecules
OPRK1 0.00459503 5.2 EPHA7 3.26 3 108 113 ITGA9 1.78 3 107 5.4
PCDH10 0.000751492 3.1 PCDH8 2.53 3 107 102.4 GREM1 0.00432727 6.1
BMPR1B 0.000134191 2.9 EPHA4 4.50 3 106 83.5 CD59 1.27 3 106 6.5
CD44 0.0151098 2.3 PCDH18 7.34 3 108 81.7 CD82 1.48 3 106 6.5
FGFR2 0.000195311 2.2 OPRK1 2.49 3 107 72.8 CD164 1.26 3 106 9.9
FZD9 0.0148514 2.2 CD24 3.75 3 107 58.3 ITGB3 9.77 3 108 11.3
PTCH1 0.000635444 2.2 CD200 3.42 3 107 45.8 ITGB1 1.84 3 105 11.5
ITGA10 0.0246543 2.1 PCDHB10 3.86 3 107 31.6 ITGA5 1.08 3 108 13.8
PCDH8 0.0396394 1.8 CDH2 1.81 3 107 24.4 CD276 7.93 3 109 15.4
FZD8 0.00291429 1.8 CDH10 3.65 3 107 22.3 LIFR 1.09 3 108 17.2
FGFRL1 0.00167931 1.6 FZD2 2.34 3 108 20.4 CD58 1.14 3 108 16.2
SDC4 0.0224326 1.5 ITGB8 5.95 3 107 19.9 CD55 2.10 3 106 18.6
Growth Factors/Morphogens FZD3 9.66 3 106 19.2 CD109 3.40 3 108 19.3
GDF5 0.000129624 4.4 CD146/MCAM 1.60 3 107 17.8 CD46 1.06 3 107 24.2
PTHLH 0.0020495 3.8 IL11RA 6.48 3 107 16.7 CD73/NT5E 3.81 3 107 72.4
WNT16 0.0171712 2.6 FZD4 1.84 3 106 14.4 CD44 2.37 3 107 82.7
SCRG1 0.00548691 2.6 CD248 2.08 3 106 12.2 ICAM1 1.36 3 107 181.2
NOG 0.00513526 2.4 LEPR 9.95 3 106 11.9 Growth Factors/Morphogens
GDF10 0.0280791 2.2 BMPR1B 2.42 3 105 11.5 DKK1 0.000128204 42.2
Transcription Factors PCDH7 1.84 3 105 10.7 DKK2 3.54 3 106 41.1
FOXC1 6.99 3 107 3.4 CADM1 1.84 3 107 10.1 NOG 2.07 3 105 34.2
SOX5 6.69 3 106 3.4 EGFR 1.58 3 105 9.6 FGF13 2.91 3 106 27.3
SOX6 8.27 3 106 3.3 GABRB3 1.71 3 106 9.4 FST 1.77 3 106 23.6
NKX3.2 3.91 3 105 3 CD56/NCAM1 7.77 3 105 9.3 GDF10 6.70 3 105 22.5
SOX9 7.83 3 107 2.9 CD53 1.08 3 106 7.9 GDF5 1.50 3 105 12.2
FOXC2 6.43 3 105 2.7 ACVR2B 1.47 3 105 6 PDGFC 6.37 3 108 9.5
HOXA13 0.0476803 2.6 PCDHB2 2.77 3 106 5.7 FGF7 1.27 3 106 9.3
GLI3 0.000145827 2.3 ITGA4 4.67 3 106 5.7 FGF9 1.28 3 105 6.6
FOXA3 0.0336405 2.2 CD166/ALCAM 5.02 3 105 5.4 WNT5A 0.000433419 5.7
FOXP2 0.00180209 2.1 PTCH1 2.50 3 106 5.3 DKK3 0.000224373 3.7
HOXD11 0.0379312 2 PCDHB16 6.12 3 106 5.3 BMP1 3.17 3 107 3.4
(Continued on next page)
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Table 1. Continued
Prechondrocytes versus Total Limb
Cells at 5–6 Weeks
Embryonic Prechondrocytes at 5–6 Weeks versus Immature Resting Fetal Chondrocytes
at 17 Weeks
Gene
Symbol p Value
Fold
Change Gene Symbol p Value
Fold
change Gene Symbol p Value
Fold
Change
FOXP4 1.79 3 105 1.9 PCDH9 0.000170686 5.2 BMP2 9.14 3 107 5.5
HOXD10 0.0186307 1.9 CD84 0.000524974 4.2 TGFB1 1.44 3 106 7.1
FOXP1 0.000117552 1.7 PCDH10 0.000524021 3.7 NGF 5.04 3 109 15.7
SOX8 0.00749 1.7 CD151 1.17 3 105 4.7 BMP6 3.56 3 105 20.7
GLI2 0.00126504 1.6 NOTCH1 2.34 3 108 4.9 TGFB2 1.01 3 107 37.2
GLI1 0.000173377 1.5 CD74 1.26 3 106 5.3 LIF 2.28 3 109 76.8
See also Table S2.
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mesenchymal cells is observed until 11–12 weeks (Fig-
ure S2; data not shown); therefore, at 17 weeks of human
development, the vast majority of chondrocytes present
in articular and growth plate regions will be fully specified.
The transition of mesenchymal ancestors to highly
compact, rounded chondrocytes has previously been
shown to be associated with major changes in cytoskeletal
composition (Woods et al., 2007). To identify specific
surface antigens associated with the transition step, we
compared the gene expression data of prechondrocytes
(primitive cartilage-committed progenitors present only
during de novo condrogenesis) with resting periartic-
ular chondrocytes (immature definitive chondrocytes)
(Figure 3B; Table 1). These data showed that thematuration
of prechondrocytes into periarticular chondrocytes was
associatedwith theprogressive loss of severalmesenchymal
genes, including MCAM (encodes CD146), NCAM1
(encodes CD56), CD24, CDH2 (encodes N-cadherin) and,
to a lesser extent, ALCAM (encodes CD166; Table 1). In
contrast, other genes encoding surfacemolecules including
CD44,NT5E (encodes CD73), and SDC4weremarkedly up-
regulated in resting periarticular chondrocytes (Table 1).
Complete lists of gene expression data are included in Table
S2. The expression of several key genes markedly changed
in microarray analysis was confirmed by quantitative PCR
(Figure 3D). IPA was then applied to identify functional
groups of genes that changed during this transition;
changes in cell morphology and cell movement were
among the top activated categories, further indicating
significant changes in cell shape in motility during chon-
drogenic maturation and differentiation (Figure 3E). Addi-
tionally, the microarrays identified several growth factors
highly expressed in resting periarticular chondrocytes
(Table 1), including transforming growth factor b 1 and 2
(TGFB1 and 2) and leukemia inhibitory factor (LIF).Stem Cell RWe next assessed the expression pattern of mesen-
chymal markers CD166 and CD146 in different cartilage
compartments at 8 and 12 weeks of development to
map cells with a prechondrocyte phenotype at more
advanced stages. Similar to 5- to 6-week limbs, at
7–8 weeks of development, cells in the presumptive joint
or ‘‘interzone’’ regions expressed CD146 (Figure S2), indi-
cating the presence of prechondrocytes. However, by
11–12 weeks of development (and at later stages), the
expression of CD146 was completely absent on the vast
majority of chondrocytes, including resting periarticular
chondrocytes and hypertrophic chondrocytes (Figure S2),
suggesting the absence or minimal numbers of cells
undergoing de novo chondrogenesis at this stage. Interest-
ingly, despite the minimal levels of CD166 on prechon-
drocytes, this marker, as well as CD146, was highly
expressed on the most primitive outer layer of cells in
the perichondrium (another source of chondrocyte pre-
cursors) surrounding diaphyseal and metaphyseal regions
of the bone rudiment. Importantly, the levels of CD166
and CD146 expression in the perichondrium markedly
decreased after progenitor cell differentiation into mature
chondrocytes (Figure S2).
Expression of CD146 was not exclusive to prechondro-
cytes. This marker was expressed at much higher levels
on endothelial and perivascular cells and also on skel-
etal myoblasts (Figures S3A and S3B) at 6–8 weeks of
development. Analysis of perivascular mesenchymal
cells in situ revealed no or minimal expression of CD73
but positivity for CD166, making them phenotypically
distinct from CD73+CD166low/neg prechondrocytes and
definitive chondrocytes (Figure S3A). The majority
of skeletal myoblasts, as well as dermal fibroblasts, ex-
pressed CD166 at 5–8 weeks of development were also
phenotypically distinct from chondrocytes at this stage
(Figures S3B and S3C).eports j Vol. 1 j 575–589 j December 17, 2013 j ª2013 The Authors 579
Figure 2. Prechondrocytes in Chondrogenic Condensations at
6–7 Weeks Are Proliferating and Express BMPR1B and CD146,
and Are CD44low/CD166low/neg
(A) An overview of the upper limb at 6–7 weeks showing two focal
planes assessed at high magnification.
(B and C) Immunohistochemistry for a panel of mesenchymal and
chondrogenic antigens demonstrated that prechondrocytes at
the periphery of condensations (B) express BMPR1B and can be
distinguished from differentiated cartilage cells in the central areas
of condensations and hypertrophic chondrocytes in the proximal
limb region (C) via the expression of CD146, negativity for the
chondrogenic matrix molecule collagen II, and low positivity for
CD44 and CD166.
Positive signal is shown in brown color (3, 30-diaminobenzidine),
and nuclei were counterstained with hematoxylin. Scale bar,
20 mm. See also Figure S1.
580 Stem Cell Reports j Vol. 1 j 575–589 j December 17, 2013 j ª2013 The
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Chondrogenic Differentiation of Human PSCFinally, we assessed the expression levels of integrin alpha
5/CD49e in developing human chondrocytes. CD49e has
been previously shown to mark a small cohort of cartilage
progenitors located in the surface layer of adult articular
cartilage (Williamsetal., 2010).At8,12, and17weeks,nearly
all fetal chondrocytes as well as surrounding mesenchymal
cells expressed CD49e (not shown), indicating limited
significance of this marker for the tracking of the chondro-
genic subpopulations in early human development.
In summary, microarray and immunophenotypic anal-
ysis revealed a unique genetic signature of the most primi-
tive human prechondrocytes and also identified a number
of surface molecules and growth factors markedly up- or
downregulated during prechondrocyte transition to defini-
tive restingandmorematurehypertrophicchondrocytes. In
addition, these data revealed CD166 as a potentially power-
ful surface marker for delineating cells of the chondrogenic
lineage fromothermesenchymal lineages, includingmulti-
potent cell types such as the perichondrium.
Isolation ofHumanPrimaryChondrocyte Populations
by Flow Cytometry
Based on the IHC andmicroarray data, it was predicted that
the earliest prechondrocytes are highly enriched in the
CD166low/negCD73+ fraction of total limb cells and that
the most primitive subset will also express low levels of
CD146. Flow cytometric analysis of the total limb mesen-
chyme clearly showed the presence of a heterogeneous
CD166low/neg CD73+ subset that could be further subdi-
vided by the level of CD146 intensity: CD146high and
CD146low/neg (Figure 4A). Fromthis subset,wedepleted line-
age-positive cells using CD45 and CD235 (glycophorin A)
for the removal of hematopoietic cells, CD324/epithelial
cadherin (E-CAD) to exclude keratinocytes, CD34 for the
exclusion of adventitial cells, and CD31 for the exclusion
of endothelial cells. CD166low/negCD146highCD73+ cells
were marked and excluded during lineage depletion,Authors
Figure 3. Prechondrocytes Are Enriched for the Expression of Mesenchymal Genes as Compared to Definitive Resting Chondrocytes
(A) Resting chondrocyteswere isolatedby dissecting a200-mm-thick layer of cells fromthe femoral epiphysis as indicatedby the dotted line.
(B) Unsupervised clustering of 1,222 genes differentially expressed between prechondrocytes (PC; six independent specimens) and
definitive 17-week fetal periarticular resting chondrocytes (RC; three independent specimens).
(C) Principal component analysis performed on all probe sets demonstrated the reproducibility of data between biological replicates.
(D) Expression differences of key genes enriched at specific stages of chondrocyte differentiation were validated by quantitative PCR.
Expression in total limb cells (TLC) is shown for comparison. Results represent mean ± SD; six independent specimens. NS, not statistically
significant.
(E) Global functional analyses, network analyses, and canonical pathway analyses were performed using Ingenuity Pathway Analysis. The
most upregulated functional groups in prechondrocytes versus definitive resting chondrocytes are shown.
See also Figure S2.
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cells positive for CD31 (data not shown). CD166low/neg
CD146low/negCD73+ cells were further subdivided into
CD44high and CD44low subsets following the expression
pattern shown for prechondrocytes and mature chondro-
cytes (Figures 1, 2, and 3).
To confirm that mature chondrocytes express high levels
of CD44 and are CD146neg, we isolated resting periarticularStem Cell Rchondrocytes from the proximal epiphysis of human
femoral bone at 17 weeks of development. Consistent with
our earlier data, no expression of CD146 or CD166 and
expression of CD44 was detected on the vast majority of
17-week resting periarticular chondrocytes (Figure 4B). In
5- to 6-week limbs, the CD44low subset represents 79% ±
7.3% of CD146low/negCD166low/negCD73+LINneg cells while
only 14.7% ± 3.1% are mature chondrocytes expressingeports j Vol. 1 j 575–589 j December 17, 2013 j ª2013 The Authors 581
Figure 4. Prechondrocytes Can Be Prospectively Isolated from Total Limb Cells based on a CD166low/negCD73+CD146low/neg
LINnegCD44low Phenotype
(A) Gating strategy used to fractionate total limb cells at 5–6 weeks of development into defined populations. The lineage cocktail used to
exclude endothelial, epithelial, and hematopoietic cells (LIN) included CD324 (E-CAD), CD31, CD34, CD45, and CD235 (GLYA).
(B) Immunophenotypic profile of definitive fetal resting periarticular chondrocytes isolated at 17 weeks of development. Note the higher
expression of CD44 on most cells compared to prechondrocytes.
(C and D) Gates labeled 1–6 (C) denote immunophenotypic populations isolated and tested for expression levels of the following diag-
nostic cartilage genes (D): SOX9, NKX3-2, COL2A1 (collagen II), and ACN (aggrecan).
(E) Fluorescence-activated cell sorted CD166low/negCD73+CD146low/negLINnegCD44low chondrogenic cells are enriched for the same genes as
LCM-isolated prechondrocytes with respect to total limb cells. Mean ± SD; four independent experiments for all quantitative PCR data. NS,
not statistically significant.
(F) Fluorescence-activated cell sorted CD166low/negCD146low/negCD73+LINnegCD44low cells also express BMPR1B at the protein level.
Positive staining is shown in brown (3, 30-diaminobenzidine), and nuclei were counterstained with hematoxylin. Scale bar, 20 mM.
(G) In vitro analysis of mesenchymal lineage potential of six populations (as described in C) revealed that some populations either lacked
chondrogenic potential (P4 and P5) or showed chondrogenic (Alcian blue staining), osteogenic (Alizarin red staining), and myogenic
differentiation (dystrophin+ myotubes; brown), reflecting their initial multipotency (P1, P2, and P3). In contrast, prospective pre-
chondrocytes (P6) uniformly generated cartilage positive for Alcian blue. Representative of three independently repeated experiments.
Scale bar, 100 mm.
See also Figure S3.
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old chondrocytes express high levels of CD44 (Figures 4A
and 4B).
We next sorted six distinct populations identified in hu-
man 5- to 6-week-old limbs (Figure 4C) by fluorescence-
activated cell sorting (FACS), isolated mRNA, and analyzed
the expression of several key chondrogenic genes,
including SOX9, NKX3-2, AGN, and COL2A1, in each of
these populations. Quantitative PCR analysis demon-
strated that CD146low/negCD166low/negCD73+CD44low cells
had the highest expression of the chondrogenic genes
across the all tested populations, not including differenti-
ated chondrocytes (Figure 4D).
To further strengthen these findings and confirm that
FACS-isolated CD166low/negCD146low/neg CD73+CD44low
cells represent the prechondrocytes isolated via LCM, we
tested the expression levels of 16 genes found to be highly
expressed in the LCM-isolated prechondrocytes in FACS-
isolated CD166low/negCD146low/negCD73+CD44low cells;
total cells depleted of prechondrocytes (Figure 4E) were
used as a negative control. In strong agreement with the
microarray data, all tested genes were upregulated in
the CD166low/negCD146low/negCD73+CD44low population,
further suggesting that this cell population represents a
highly enriched pool of the earliest prechondrocytes pre-
sent in chondrogenic condensations (Figure 4E). In addi-
tion, the expression of BMPR1B by sorted CD166low/neg
CD146highCD73+CD44low cells was confirmed by IHC (Fig-
ure 4F). However, as BMPR1B is expressed on all chondro-
cytes at 5–6 weeks, its significance for FACS isolation of
prechondrocytes at this stage is limited.
CD166low/negCD146low/negCD73+CD44low Cells
Represent Functional Human Chondrocyte
Progenitors
Next, we carried out in vitro functional studies to con-
firm the chondrogenic potential and commitment of
CD166low/negCD146low/negCD73+CD44low cells as well as
the other five populations sorted from the same limb sam-
ples (Figure 4C). In vitro pellet assays, designed to test
mesenchymal lineagepotential, performedonCD166low/neg
CD146low/negCD73+CD44low (population 6) cells isolated
from 5- to 6-week limbs confirmed their predominate chon-
drogenic potential (Figure 4G), while other populations
had either no chondrogenic potential (populations 4 and
5) or limited ability to form cartilage tissue (populations 1
and 2). Populations 1, 2, and 3 also showed very prominent
osteogenic potential, indicating the presence ofmultipotent
cells or/and multiple lineage-committed progenitors in
these fractions (Figure 4G). Myogenic potential (formation
of myofibers) was especially prominent in population 2.
Thesedataconfirmedthepredominate chondrogenicpoten-
tial of CD166low/negCD146low/negCD73+CD44low cells andStem Cell Rfurther highlighted the utility of CD166 as amarker for cells
with potential to generate other mesenchymal lineages.
BMPR1B and LIFR Are Restricted to Resting
Chondrocytes at Later Developmental Stages
Immunohistochemistry showed that BMPR1B is expressed
on prechondroyctes at 5–6 weeks of development (Table 1;
Figure 4F) and alsomore broadly onmoremature chondro-
cytes in the center of chondrogenic condensations at 6–
7 weeks (Figure 2C). Starting in 8-week limbs and progress-
ing through gestation, BMPR1B is expressed primarily on
resting chondrocytes in the surface layers of articular
cartilage; more differentiated chondrocytes located in
deeper zones did not express BMPR1B (Figure 5A). Interest-
ingly, a similar pattern of expression for LIFR was also
observed, while both resting periarticular chondrocytes
and adjacent synovial cells expressed the ligand LIF
(Figure 5B). In postnatal articular cartilage (Figure 5C),
BMPR1B+ and LIFR+ cells were also clearly detectable in
the superficial zone coinciding with the known location
of the most primitive cartilage progenitor pool (Dow-
thwaite et al., 2004), but not in the more differentiated
deep zone. Of note, not all BMPR1B+ cells expressed LIFR.
In postnatal growth plates, where chondrogenesis is still
active, immature chondrogenic cells were also BMPR1B+
and LIFR+, while differentiated chondrocytes were negative
for both (Figure 5D). Finally, BMPR1BandLIFR arepreferen-
tially expressed on cells located in the superficial zone
versus chondrocytes present in the deep zone in articular
cartilage fromaknee joint evenat 60yearsof age (Figure5E).
Similar to fetal joints, synovial cells in older adult joints
express LIF (Figure 5F). To further confirm that BMPR1B is
enriched on less differentiated chondrocytes after de novo
chondrogenesis is completed (after 12 weeks of develop-
ment), we isolated BMPR1B+ and BMPR1B chondrocytes
from 17-week fetal limb specimens by flow cytometry and
compared the expression levels of the immature chondro-
cyte gene SOX9 and highly specific hypertrophic marker
COL10A1 in both sorted populations (Figure 5G). BMPR1B+
chondrocytes expressed 10-fold-higher levels of SOX9 but
had much lower levels of COL10A1. Together, these data
implicate BMPR1B and LIFR as potential surface markers
for immature chondrocytes after the culmination of de
novo chondrogenesis and throughout the human lifespan.
The Generation and Maintenance of Prechondrocytes
from PSC-Derived Mesenchyme Is Marked by the
Progressive Loss of CD166 Expression and Acquisition
of BMPR1B
We next wanted to determine if the surface markers identi-
fied during human development could be applied to the
generation of chondrocytes from human PSCs. Our
group has recently described a multipotent embryoniceports j Vol. 1 j 575–589 j December 17, 2013 j ª2013 The Authors 583
Figure 5. BMPR1B and LIFR Delineate Resting
Chondrocytes after De Novo Chondrogenesis
(A) Developmental dynamics of BMPR1B
expression in human chondrocytes. BMPR1B is
highly expressed in resting periarticular chon-
drocytes at 8, 12, and 17 weeks of development
but is clearly absent in hypertrophic chon-
drocytes after 12 weeks. Positive signal is shown
in brown color (3, 30-diaminobenzidine), and
nuclei were counterstained with hematoxylin
(blue).
(B) LIFR is expressed by resting chondrocytes in
the periarticular region and not by hypertrophic
chondrocytes, while LIF is expressed by both
resting chondrocytes and neighboring synovial
cells.
(C) In postnatal articular cartilage, resting
chondrocytes in the superficial zone (negative
for Safranin O and fast green staining) express
both BMPR1B and LIFR, while hypertrophic
chondrocytes in the deep zone (positive for
Safranin O) are negative for both proteins.
(D) Reserve chondrocytes in the growth plate
region at the same stage also express BMPR1B
and LIFR; hypertrophic chondrocytes are
negative.
(E and F) At later adult stages, a subset of
BMPR1B+ and LIFR+ cells (E, arrows) remain in
the surface layer of normal articular cartilage
from the knee joint, while LIF (F) is secreted by
synovial cells. In all panels, positive staining
is shown in brown (3, 30-diaminobenzidine);
nuclei were counterstained with hematoxylin.
Scale bar, 50 mm.
(G) BMPR1B+ cells isolated using FACS from 17-
week periarticular regions evidence enrichment
for the chondrocyte progenitor gene SOX9, but
express much lower levels of the hypertrophic
gene COL10A1 with respect to BMPR1Bneg cells
isolated from the same region. Mean ± SD; four
independent experiments.
See also Figure S4.
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expression of surface markers of epithelial-to-mesen-
chymal transition (Evseenko et al., 2010). Our previous
studies showed that the EMP population gives rise to
lineage-restricted hematoendothelial, cardiovascular, and
mesenchymal progenitors (functionally resembling em-
bryonic myogenic, osteogenic, and chondrogenic mesen-
chyme). The earliest skeletogenic mesenchymal cells were
identified by high levels of CD166, CD146, and PDGFRa
expression and lacked expression of CD326, CD34, and
KDR (Evseenko et al., 2010). The earliest mesenchymal
cells expressed no or minimal levels of BMPR1B. Although
PSC-derived mesenchymal progenitors could be differenti-
ated into osteogenic, myogenic, adipogenic, and chondro-
genic cells, the onset of chondrogenic differentiation and
immunophenotypes of emerging chondrocytes and transi-
tion to hypertrophic chondrocytes was not defined.
We hypothesized that the previously described multipo-
tent mesenchymal population generated from human
PSCs during mesodermal differentiation was analogous to
mesenchymal progenitors found in limb rudiments prior
to the onset of chondrogenesis.We further predicted, based
on our developmental studies, that chondrogenic differen-
tiation of these cells could be tracked by the downregula-
tion of CD166 and the acquisition of BMPR1B by cells
resembling primary prechondrocytes/resting chondrocytes
while hypertrophic chondrocytes generated from PSCwere
expected to be BMPR1Bneg. To test this hypothesis, PSC-
derived mesenchymal cells were plated into micromass
high-density culture tomimic chondrogenic condensation
(Figure 6A) in the presence of chondrogenesis-inducing fac-
tors SonicHedgehog (SHH) and BMP4 aswell as prosurvival
factors FGF2 and IGF1 in serum free conditions. The chon-
drogenic effects of SHH at the progenitor stage have been
well documented (Murtaugh et al., 1999; Zeng et al.,
2002). In the current study, the SHH receptor Patched 1
(PTCH1)was found tobeon the list of themost upregulated
genes in prechondrocytes at 5–6 weeks of development
(Table 1), and its expression was also confirmed on PSCs
and PSC-derived mesenchyme (not shown).
Based on our microarray data and published literature,
we hypothesized that transforming growth factor b
(TGF-b) and LIF signalingmay induce committed chondro-
cytes to remain in an undifferentiated state (Table 1), while
BMP signaling may promote hypertrophy. Several BMP
superfamily members including BMP2, BMP4, and BMP7
as well as GDF5 have previously been shown to induce
chondrogenesis in vivo and in vitro, and prolonged expo-
sure to these factors is known to drive chondrocytematura-
tion and hypertrophy (Coleman et al., 2013; Zhang et al.,
2003; Bandyopadhyay et al., 2006; Coleman and Tuan,
2003; Grimsrud et al., 1998). To test this hypothesis in
our system, we cultured human primary fetal chondrocytesStem Cell Rwith various cytokines (Figure S4). BMP4 and BMP7 had
the most prominent stimulatory effect on COL10A1 gene
expression in validation studies, indicative of the adoption
of a hypertrophic phenotype; inclusion of TGF-b1 and LIF
individually had a small effect, but the combination of the
two significantly prevented the induction of COL10A1
expression during culture.
We then applied these conditions to PSC-derived cells.
Generated aggregates were cultured for 5, 10, and 15 days
and then analyzed for chondrogenic characteristics
(Figures 6B–6D). To further dissect the molecular profile
of cultured cells, we dissociated aggregates for FACS anal-
ysis at days 5, 10, and 15 of culture. At day 10, BMPR1B
showed the highest level of expression; this surface mole-
cule was expressed on 60%–70% of cells cultured in the
presence of LIF and TGF-b1, while levels of CD166 were
downregulated, suggesting that the majority of mesen-
chymal cells transitioned into phenotypic prechondro-
cyte/resting (immature) chondrocyte (Figure 6B). In
contrast, only 2%–4% of cells cultured in the presence of
BMP7 were BMPR1B+, consistent with the low levels of
expression of this receptor on hypertrophic chondrocytes
(Figure 6B). Quantitative PCR analysis revealed signifi-
cantly higher levels of the chondrocyte maturation-associ-
ated genes MTN1, RUNX2, and COL10A1 in aggregates
cultured in the presence of BMP7, while genes whose
expression is enriched in superficial zone of articular carti-
lage where resting chondrocytes are located (BMPR1B,
PRG4, and SOX9) were elevated in BMPR1B+CD166low/neg
cells isolated from aggregates cultured in the presence of
TGF-b1 and LIF (Figure S5A). PCR analysis confirmed pro-
gressive downregulation of BMPR1B gene expression,
initially expressed on aggregated mesenchymal cells at
the time of chondrogenic induction, in cultures exposed
to BMP7 for more than 10 days (Figure S5B). In both cul-
tures, most cells expressed CD73 and CD44, indicating
limited significance of these markers for the tracking of
chondrogenic cells generated from PSCs (not shown).
We next determined the quantitative expression levels of
chondrogenic genes in three distinct populations isolated
from aggregates cultured in the presence of TGF-b1 and LIF
by FACS: (1) CD166+BMPR1Blow/neg, (2) CD166low/neg
BMPR1B+, and(3)CD166low/negBMPR1Blow/neg cells.Quanti-
tativePCRanalysis showed thatonlyCD166low/negBMPR1B+
cells expressed both progenitor/interzone genes (SOX9
and GDF5) as well as COL2A1, while minimal levels of
hypertrophic chondrocyte marker COL10A1 were detected.
CD166+BMPR1Blow/neg cells showed minimal expression of
chondrogenic genes, while CD166low/negBMPR1Blow/neg evi-
denced an expression profile more typical for chondrocytes
undergoing terminal differentiation and hypertrophy (Fig-
ure 6C), indicating that this population is enriched for
terminally differentiated chondrocytes.eports j Vol. 1 j 575–589 j December 17, 2013 j ª2013 The Authors 585
Figure 6. Emerging PSC-Derived Chon-
drocytes Can Be Enriched Using a
Similar Strategy Defined by Chondrocyte
Ontogeny in Vivo
(A) Experimental scheme depicting the
generation of PSC-derived chondrocytes
following the induction of mesenchyme
differentiation.
(B) Immunophenotypic profiles used to
isolate prechondrocyte-like and mature
chondrocytes generated from PSC-derived
mesenchymeafter chondrogenic aggregation.
(C) Expression of chondrogenic genes in
CD166low/negBMPR1Bneg, CD166low/
negBMPR1B+, and CD166+BMPR1Bneg cells
isolated from chondrogenic aggregates
cultured in the presence of LIF and TGF-b1.
CD166low/negBMPR1B+ cells expressed higher
levels of prechondrocyte genes compared
to the other two populations and showed
significantly lower expression levels of
COL10A1 than CD166low/negBMPR1Bneg cells
(mean ± SD; three independent experi-
ments); NS, not statistically significant.
(D) Chondrogenesis-committed mesen-
chymal cells cultured in the presence of TGF-
b1 and LIF (top row) generate cartilage
matrix positive for Alcian blue and collagen
II, with minimal levels of collagen I and X,
while mesenchymal cell aggregates cultured
in the presence of BMP7 show hypertrophic
morphology and deposit high levels of
collagen X (bottom row). Scale bar shown for
images is 100 mm.
(E) a. PSC-derived CD166low/negBMPR1B+ cells
were isolated by FACS, labeled with PKH67
green, and deposited into explants from fetal
hip joints. b. Explant viewed from above at
the time of harvest showing persistence of
PKH67-labeled cells after 14 days. c. Trans-
verse section through the explant. d. Uniform
Collagen II staining of chondrocytes in the
uninjured surface of the explant. e. PSC-
derived prechondrocyte-like cells integrate
into the injured region and produce collagen
II, but not collagen X (f). Scale bar, 50 mm.
See also Figure S5.
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showed significant levels of collagen II and glycosaminogly-
cans present in all aggregates, confirming that all cultures
were undergoing chondrogenesis (Figure 6D). However,
cells cultured in the presence of BMP7 had hypertrophic
morphology and deposited significantly higher levels of
collagen X (Figure 6D). We next tested the multilineage
potential of the CD166low/negBMPR1B+ cells. In contrast
to multipotent mesenchymal cells derived from PSCs586 Stem Cell Reports j Vol. 1 j 575–589 j December 17, 2013 j ª2013 Thedescribed in our previous studies (Evseenko et al., 2010),
this population showed no or minimal osteogenic, adipo-
genic, and myogenic potential (Figure S5C). Finally, sorted
and PKH67-labeled (green) CD166low/negBMPR1B+ were
implanted into the surface layer of femoral cartilaginous
epiphysis dissected from fetal 17-week specimens and
cultured. Immunofluorescent analysis performed 14 days
later showed clear integration of PSC-derived cells into the
existing cartilage tissue, robust deposition of collagen II,Authors
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Chondrogenic Differentiation of Human PSCand lackof thehypertrophicmarkercollagenX in thematrix
surrounding implanted cells (Figure 6E). Overall, these ex-
periments revealed thatCD166low/negBMPR1B+ cells derived
fromPSCs represent cartilage-committed cells with amolec-
ular and functional profile similar to undifferentiated pre-
chondrocytes/resting chondrocytes present during human
development and that LIF and TGF-b signaling can be
used to promote an nonhypertrophic state in these cells.DISCUSSION
In summary, we have used LCM and FACS to isolate
and characterize for the first time the earliest cartilage-
committed and structurally distinct prechondrocytes and
definitive chondrocytes during early human embryogen-
esis. Using immunophenotypic markers, gene expression,
and functionality, we showed that a developmental
paradigm allows for the generation and enrichment of
prechondrocytes/immature chondrocytes during PSC dif-
ferentiation based on the expression patterns of BMPR1B
and CD166 and signaling pathways important during
development. Altogether, these data detail a potential
approach for the generation of functional definitive hu-
man chondrocytes from PSCs that may drive newmethod-
ologies for cartilage tissue engineering.
We first identified surface markers that distinguish
the earliest prechondrocytes from nonchondrogenic cells
types; subsequent comparison of prechondrocytes with
differentiated, definitive resting (immature) chondrocytes
located in the superficial periarticular regions within fetal
joints led to the identification of a combination of surface
markers enriched on both cell types and demarcating them
from chondrocytes undergoing maturation and hypertro-
phy. The expression of CD166 and CD146 has been previ-
ously reported to mark highly invasive and migratory
mesenchymal cells in normal and pathological condi-
tions (Swart, 2002; Swart et al., 2005; Zeng et al., 2012).
Moreover, CD146 has been shown to be directly involved
in the process of epithelial-to-mesenchymal transition
through the positive regulation of Slug (Zeng et al.,
2012). In good agreement with these studies, loss of the
mesenchymal phenotype and transition of cartilage-
committed mesenchymal cells or prechondrocytes to
differentiated nonmotile chondrocytes is associated with
the progressive loss of CD166 of CD146.
A combination of TGF-b1 and LIF was used in this study
to inhibit excessive cartilage maturation and hypertrophy
and favor the generation and persistence of primary and
PSC-derived cartilage progenitors. Although the antidiffer-
entiation properties of LIF have been well documented in
the fields of pluripotent stem cells, hematopoiesis, and
neurobiology (Audet et al., 2001; Bonaguidi et al., 2005;Stem Cell RSmith et al., 1988), their role in the regulation of chondro-
genesis is completely novel. Synovial cells of both fetal
and adult normal joints highly express LIF (Figure 5), indi-
cating that this factor may be implicated in the mainte-
nance of the most primitive progenitors located in the
superficial layer of articular cartilage. Indeed, LIFR was pri-
marily localized in resting chondrocytes also positive for
BMPR1B, while LIF and TGF-b1 and TGF-b2 were among
the top molecules enriched in definitive resting chondro-
cytes (Table 1). Moreover, our validation studies on fetal
chondrocytes suggest that these factors may prevent chon-
drocyte maturation and hypertrophy. More studies are
needed to characterize BMPR1B+ cells in adult joints and
fully define the role of LIF in the regulation of these cells.
Our data suggest that utilizing the LIF signaling axis may
further advance engineering of functionally superior
cartilage implants for joint surface repair in patients with
cartilage injury or arthritis.
In summary, we have for the first time characterized
the earliest stages of human chondrogenic development.
Starting with the distinct morphological identity
of prechondrocytes, we found a unique combination
of surface markers (CD166low/negCD146low/negCD73+
CD44lowBMPR1B+) that distinguishes these cells from other
populations in the developing limb and directs the enrich-
ment of chondrogenic progenitors. Subsequent comparison
of the gene expression profile of prechondrocytes with
resting periarticular chondrocytes, in conjunction with
immunohistochemical analysis, led to the identification of
the LIF, TGF-b, and BMP signaling pathways as potential
regulators of the differentiation state of chondrocytes.
Application of these findings permitted the generation of
functional immature chondrocyte cells from pluripotent
stem cells. The identification of specific phenotypic
signatures for primitive prechondrocytes and definitive
resting chondrocytes will now permit further delineation
of the molecular regulation of chondrogenic commitment,
growth plate versus articular cartilage fate choice, and hy-
pertrophy in humans. Itmay also contribute to understand-
ing of how these processes are affected during aberrant
chondrogenesis in disease states. Finally, characterization
of the earliest primary chondrocytes provides essential
knowledge for the generation of purified cartilage cells
from PSCs and represents a unique target for cartilage tissue
engineering.EXPERIMENTAL PROCEDURES
Human fetal tissues were obtained from Novogenix Laboratories
following informed consent and elective termination. Develop-
mental age was determined by ultrasound. Adult articular
chondrocytes and synovial membrane were obtained from
National Disease Research Interchange. Postnatal, healthy,eports j Vol. 1 j 575–589 j December 17, 2013 j ª2013 The Authors 587
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Chondrogenic Differentiation of Human PSCparaffin-embedded joint and growth plate specimens (N = 3) were
kindly donated by Dr Marcel Karperien from the University of
Twente (Netherlands). All donated material was anonymous and
carried no personal identfiers. Differentiation potential of PSCs
was studied using the H1 cell line (Madison, WI) or fully validated
lines UCLA3 or HIPS23 derived at the University of California,
Los Angeles (Los Angeles, CA). Fetal specimens, adult specimens,
and/or PSC-derived lineages were analyzed using LCM, flow
cytometry, microarray analysis, PCR, and immunohistochemistry
as well as chondrogenic, myogenic, adipogenic, and osteogenic
assays. Detailed description of all methods and statistical tests
used for analyses of data is available in the Supplemental Experi-
mental Procedures.ACCESSION NUMBERS
The NCBI Gene Expression Omnibus accession number for micro-
array data reported in this study is GSE51812.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, five figures, and two tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2013.10.012.
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